Vir Biotechnology, Inc. VIR Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Vir Biotechnology, Inc. (VIR) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $685K in Q1 2026.
- How has Vir Biotechnology, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Vir Biotechnology, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 1493.0% year-over-year, from $43K to $685K.
- What is the long-term trend for Vir Biotechnology, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 2 years (2023 to 2025), Vir Biotechnology, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -60.8% compound annual growth rate (CAGR), from $130K to $20K.